-
Listing
Strengthening Europe’s strategic autonomy through capital marketsCzechoslovak Group lists on EuronextRead moreWorld’s largest defence IPO ever recorded.
Learn more about Euronext’s initiatives to enhance financing and visibility for European aerospace and defence companies -
Trading
Where European Government Bonds meet the futureFixed Income derivativesRead moreTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingRead moreEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeRead moreEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Read moreThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesRead moreThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Read moreShaping capital markets for future generations
Pherecydes Pharma lists on Euronext Growth Paris
05/02/2021
Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, opens the trading day in Paris.
Pherecydes Pharma is specialized in the research and development of anti-infective therapies based on bacteriophages. Phagotherapy is an innovative approach to treat bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells.